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ScienceDirectT cells play a critical role in tumor immune surveillance as
evidenced by extensive mouse-tumor model studies as well as
encouraging patient responses to adoptive T cell therapies and
dendritic cell vaccines. It is well established that the interplay of
tumor cells with their local cellular environment can trigger events
that are immunoinhibitory to T cells. More recently it is emerging
that the tumor vasculature itself constitutes an important barrier
to T cells. Endothelial cells lining the vessels can suppress T cell
activity, target them for destruction, and block them from gaining
entry into the tumor in the first place through the deregulation of
adhesion molecules. Here we review approaches to break this
tumor endothelial barrier and enhance T cell activity.
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Introduction
T lymphocytes play a key role in tumor immune surveil-
lance through T cell receptor (TCR)-mediated recognition
of tumor associated antigens that have been processed and
presented as peptides (p) at the tumor cell surface by major
histocompatibility complex (MHC) molecules [1]. Activat-
ed CD8+ cytotoxic T cells are able to directly kill malignant
cells upon TCR/pMHC engagement by mechanisms in-
cluding perforin/granzyme secretion and FasL/Fas bind-
ing, and, along with CD4+ helper T cells, can secrete
various cytokines/chemokines to direct the activities of
other immune cells [2,3]. Several clinical studies, including
our own in epithelial ovarian cancer, have reported a posi-
tive correlation between patient survival and the presence
of tumor infiltrating lymphocytes (TILs) [4–7]. Moreover,
clinically significant anti-tumor activity has been achievedwww.sciencedirect.com for dendritic cell (DC) vaccines [8,9] and for adoptive T cell
therapies with TILs, and both TCR- and chimeric antigen
receptor (CAR)-engineered T cells [10,11,12,13,14,
15,16,17]. In order to improve patient outcome, important
research efforts have focused on optimizing the ‘fitness’ of
vaccine-induced or transferred T cells, including their state
of differentiation and phenotype for enhanced persistence,
proliferation, homing, etc. [18] and their receptor qualities
such as specificity and binding kinetics/affinity and avidity
[19–21]. In addition, the characterization of different solid
tumor microenvironments and the ways in which T cell
activity is inhibited, so that it may be therapeutically
reversed, is a field of intense study [22,23–25].
Solid tumors are highly heterogeneous in nature, com-
prising divergent cancer cells and host stromal cells that
are embedded within an extracellular matrix and nour-
ished by an aberrant vasculature (Figure 1a). The dynam-
ic interplay of tumor cells with their surrounding matrix
and local cellular microenvironment composed of various
immune cell infiltrates, fibroblasts, etc., affects gene
expression and the patho-physiological characteristics
of the tumor, including progression and response to
therapies [26]. In general, T cells that reach the tumor
bed after an initial priming in the tumor-draining lymph
nodes or tumor stroma face a hostile environment, in-
cluding the downregulation of MHC molecules and co-
stimulatory ligands, as well as the upregulation of inhibi-
tory receptors like programmed cell death protein ligand
1 (PD-L1) on tumor cells. They can also encounter
immunosuppression by regulatory T cells (Tregs), mye-
loid derived suppressor cells (MDSCs), and tumor-asso-
ciated macrophages (TAMs), as well as a plethora of
soluble inhibitory factors such as IL-6, IL-10, arginase
(Arg)1, and TGFb, various metabolites like adenosine,
depleted tryptophan levels as a result of indoleamine 2,3-
dioxygenase 1 (IDO-1) activity, and low pH [23,27,28].
However, in many instances effector T cells do not gain
entry into the tumor bed in the first place because they are
functionally inhibited and physically blocked by the
tumor vasculature. Here we review the mechanisms by
which the tumor vasculature acts as a barrier to effector T
cells, the so-called tumor endothelial barrier, and different
therapeutic approaches being developed to ‘break it’ or
‘normalize it’ and enhance anti-tumor T cell activity.
The tumor vasculature is inhibitory to effector
T lymphocyte responses
Tumor growth is critically dependent upon neovascular-
ization to supply itself with nutrients. Although tumorCurrent Opinion in Immunology 2015, 33:55–63
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The tumor microenvironment and the tumor endothelial cell barrier. (a). The tumor microenvironment is comprised of tumor cells, an aberrant
vasculature lined by endothelial cells and supported by pericytes, stromal cells, an extracellular matrix, and a range of immune infiltrates including
T cells, regulatory T cells (Treg), myeloid derived suppressor cells (MDSCs), tumor associated macrophages (TAMs), fibroblasts and dendritic cells
(DCs). (b) T cell extravasation is dependent upon endothelial cell expression of intracellular cell adhesion molecule-1 (ICAM-1) and vasculature cell
adhesion molecule-1 (VCAM-1). Tumor derived angiogenic growth factors such as VEGF and endothelin-1 (ET-1) signal through their cognate
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derived endothelial precursor cells, so-called vasculogen-
esis [29], or from tumor stem cells in a process called
vascular mimicry, most are formed by the sprouting of
pre-existing vessels, i.e., angiogenesis [30], promoted by
an imbalance of proangiogenic factors in the microenviron-
ment. Such factors are numerous and abundantly produced,
including the most potent one, vascular endothelial growth
factor-A (VEGF) [31,32], as well as angiopoietin, basic
fibroblast growth factor (bFGF), platelet-derived endothe-
lial growth factor (PDGF), transforming growth factor
(TGF)-a, fibroblast growth factor (FGF), and placental
growth factor (PGF). These soluble factors act on a range
of tyrosine kinase receptors like VEGFR1, VEGFR2,
PDGFRA and endothelial growth factor receptor (EGFR)
to initiate signaling pathways leading to angiogenesis and
other biological events [33]. Compared to normal vascula-
tures, tumor blood vessels are characterized by having slow
and irregular blood flow, an oversized diameter that varies
along their length, erratic branching (the vessels are tortu-
ous), many dysfunctional microvessels, high red blood cell
flux, permeability/leakiness due to oversized pores, low or
absent pericyte coverage, high compression levels due to
interstitial pressure, and the vessels may lack a basement
membrane or have one that is unusually thick [34]. Overall
these properties result in low oxygen supply causing a state
of hypoxia and an accumulation of metabolic waste that can
affect immune cell function in the tumor microenviron-
ment [35] and trigger the release and activity of proangio-
genic growth factors [36,37].
In addition, several mechanisms have been described for
tumor endothelial cells (ECs) lining the vessels that spe-
cifically inhibit tumor immunity. For example, through the
downregulation and/or declustering (i.e., deregulation) of
intracellular adhesion molecule 1 (ICAM1) and vasculature
cell adhesion molecule 1 (VCAM1), which are required for
extravasation (a multistep process involving the adherence
of leukocytes to ECs and their subsequent diapedesis),
effector cells are unable to traverse the ECs into the tumor
bed [38–40] (Figure 1b). Conversely, tumor ECs have been
shown to promote Treg accumulation in the tumor through
the upregulation of molecules such as common lymphatic
and vasculature endothelial receptor 1 (CLEVER1) [41].
Like within the tumor itself, tumor ECs can selectively
upregulate inhibitory receptors of T cell activation includ-
ing PD-L1 and PD-L2 [42,43], TIM3 [44], B7-H3 [45,46],
B7-H4 [47], as well as IDO-1 [48–50] and other soluble
inhibitory molecules such as IL-6, PGE2, IL-10 and TGFb
[51–54] (Figure 1c). Moreover, tumor ECs can express the
apoptosis inducing molecules TRAIL and FasL
(Figure 1d), the latter of which we recently showed can(Figure 1 Legend Continued) receptors, VEGFR and ETBR, respectively, to
infiltration into the tumor bed. (c) The endothelium, under the influence of tu
upregulating inhibitory molecules such as PD-L1, PD-L2, IDO-1, IL-6, and IL
express FasL which leads to apoptosis of Fas-expressing T cells.
www.sciencedirect.com selectively kill effector T cells while leaving Tregs un-
harmed [55,56,57,58]. Thus, overall the tumor vascula-
ture is inhibitory to the extravasation of effector immune
cells into the tumor bed and it promotes a state of immu-
nosuppression.
Strategies to break the tumor vasculature
barrier and restore anti-tumor T cell activity
Monoclonal antibody and small molecules to block
proangiogenic factors and their receptors to normalize
the vasculature
The VEGF/VEGFR2 axis is critical for tumor growth as it
promotes proliferation, survival, migration and invasion
[59]. Moreover, it confers important immunomodulatory
activities including the ability to inhibit DC maturation
[60,61], and to promote the accumulation and activation
of Tregs and MDSCs [62]. Consequently, VEGF expres-
sion negatively correlates with intraepithelial T cell infil-
tration, and it is associated with poor patient survival [4].
Not surprisingly, antiangiogenic molecules that target
VEGF/VEGR2 are commonly used to treat cancer
patients, and bevacizumab (Avastin), a humanized anti-
VEGF monoclonal antibody (mAb) [63] was in fact the
first antiangiogenic drug to be approved by the Food and
Drug Administration for the treatment of various cancers
including glioma and metastatic colorectal cancer [64,65].
Some therapies like bevacizumab that target proangio-
genic factors not only inhibit the sprouting of new vessels
[66], but can also ‘normalize’ the vasculature. Tumor
vasculature normalization, first described by Dr. Rakeesh
K. Jain and colleagues, is a transient correction of struc-
tural and functional defects of the tumor blood vessels
that takes place when aberrant angiogenic signaling is
blocked, temporarily enabling improved oxygen and drug
delivery (e.g., chemotherapy) as well as immune cell
infiltration [31,67–69]. In addition, many antiangiogenic
drugs also promote overall immune responses; bevacizu-
mab-based therapy of colorectal cancer patients, for ex-
ample, has been shown to increase the peripheral B and T
cell compartments [70], decrease the Treg compartment
[71], and enhance the functional maturation of DCs
[72]. Small molecules targeting the tyrosine kinase
domains of VEGFR and PDGFR, such as sunitinib
and sorafenib, have also been approved for some ad-
vanced cancers [73] and can similarly lead to improved
immune responses. A reduction in Tregs and MDSCs, for
example, has been documented for metastatic renal cell
carcinoma patients treated with sunitinib [74–76]. De-
spite initial clinical responses, however, resistance to such
kinase inhibitors frequently occurs due to the redundancy
of angiogenic pathways and protection of the tumor block the expression of adhesion molecules and inhibit T cell
mor-derived factors like VEGF, can directly inhibit T cell activation by
-10, amongst many others. (d) Tumor endothelial cells can also
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58 Tumour immunologyvasculature through the recruitment of proangiogenic
inflammatory cells [77].
Monoclonal antibody, small molecule and cytokine
treatments to restore adhesion molecule expression
T cells are dependent upon both the expression levels and
clustering patterns of ICAM-1 and VCAM-1 on ECs to
extravasate into the tumor. Despite the presence of TNFa
in the tumor microenvironment, a pleiotropic cytokine that
can activate endothelium to promote T cell adhesion [78],
several mechanisms have been identified that abrogate this
effect. The expression, for example, of the proangiogenic
factors VEGF and bFGF downregulate adhesion molecule
expression [79,80]; this can be reversed with aVEGF and
abFGF mAb treatment [69]. Another critical signaling axis
in tumors is endothelin-1 (ET-1, a 21 amino acid vasoactive
peptide) and its G protein coupled receptors ETBR and
ETAR. ET-1 driven signaling can activate proliferation,
confer apoptosis resistance, induce VEGF expression, stim-
ulate new blood vessel formation and promote invasion and
metastasis, and it is now recognized as a common mecha-
nism underlying the progression of many solid tumors [81–
84]. Through the analysis of gene expression profiles for
ovarian cancers we associated the presence of ETBR with
an absence of TILs, and we further demonstrated that
ET-1/ETBR binding stimulates nitric oxide production,
consequently decreasing ICAM-1 clustering. Moreover, in
preclinical models of ovarian and lung cancer we showed
that ETBR neutralization with the selective antagonist
BQ-788 upregulates the expression and clustering of
ICAM-1 to restore T cell adhesion, increase intra tumoral
T cell infiltration, and significantly improve responses
following vaccination as well as adoptive T cell transfer
[85]. ETBR blockade probably also inhibits angiogenesis
through suppression of tumor cell derived VEGF and the
reduction of EC nitric oxide production [86,87].
Although TNFa treatment has been shown to exert
potent anti-tumor effects in animal models [88], its sys-
temic administration in phase II clinical trials yielded
minimal anti-tumor responses and was prohibitively toxic
[89,90]. New therapeutic approaches, however, have
been designed to selectively deliver TNFa to tumor
blood vessels. For example, TNFa coupled with the
CNGRC peptide motif (NGR-TNF) that specifically
interacts with CD13 (an aminopeptidase expressed by
ECs of angiogenic vessels) [91], upregulates ICAM-1 and
VCAM-1 expression as well as proinflammatory cyto-
kines, enhances T-cell extravasation and intratumoral
infiltration, improves the penetration of chemotherapies
into the tumor and their efficacy, and enhances adoptive
and active immunotherapies in various mouse tumor
models [92,93,94]. A similar compound, RGR-TNF,
has been shown to augment active and adoptive immu-
notherapy in experimental pancreatic neuroendocrine
tumors, in part by remodeling the vascular network with
less PDGFRb+ pericyte coverage, and in part through theCurrent Opinion in Immunology 2015, 33:55–63 polarization of tumor-resident macrophages to an M1
immunostimulatory phenotype [95]. Another approach
to upregulating tumor EC expression of adhesion mole-
cules, including ICAM-1, VCAM-1 and E-selectin, is by
aCD137 (4-1BB) agonist mAb therapy. CD137 is a costi-
mulatory glycoprotein expressed on activated T cells, NK
cells, DC cells, and, interestingly, also on human tumor
blood vessels [96–98]. Thus, administration of aCD137
mAb not only directly heightens anti-tumor CD8+ T cell
activity by binding to their cell surface [99,100–102], it
also stabilizes the tumor vasculature.
Active immunization against tumor vasculature antigens
Given the genetic stability and accessibility of tumor ECs,
as well as the fact that they express various angiogenic
markers that are either not present or are expressed at low
levels in normal vessels, the tumor vascular is an attractive
target for immunization [103,104]. The majority of immu-
nization strategies that have been developed and tested to
date in pre-clinical models are against VEGF/VEGFR2,
either in the form of protein pulsed DCs [104,105] or DNA
vaccines [106–111]. Responses, including tumor EC de-
struction, and the inhibition of tumor growth and metasta-
sis, are primarily CD8+ T cell-mediated. Immunizations
with both autologous and xenogeneic endothelium have
also yielded encouraging preclinical responses [112,113].
More recently, a DNA vaccine administered with tetanus
toxoid and targeting tumor endothelial marker 1 (TEM1), a
protein which is expressed on tumor ECs [114–118], as well
as tumor-associated pericytes [119] and fibroblasts [120],
was shown able to enhance intratumoral infiltration of
endogenous CD3+ T cells as well as delay tumor progres-
sion in mice [121].
CAR-T cell targeting of tumor vasculature antigens
Over the past few years, CAR T cells against tumor
vasculature antigens, including VEGFR1, VEGFR2 and
prostate specific membrane antigen (PSMA; glutamate
carboxypeptidase II) [122], have also been assessed in
various pre-clinical mouse models. CARs are hybrid recep-
tors comprising an antigen-targeting moiety, typically in
the form of a single chain variable antibody fragment
(scFv), fused with a linker, a transmembrane domain,
the intracellular signaling module of CD3z, and various
combinations of co-stimulatory domains such as CD28, 4-
1BB (CD137), and OX40 (CD134) [123]. Overall, these
studies have demonstrated that vasculature-targeting CAR
T cells can significantly delay tumor growth. The co-
expression of IL-12 or IL-15 was also shown to enhance
their efficacy through increased tumor infiltration, expan-
sion, and in vivo survival of the transferred cells
[124,125,126]. Finally, the combination of CAR T cells
against VEGFR2 and T cells specific for the melanoma
tumor antigens gp100 and TRP-1 resulted in increased
intratumoral T cells, synergistic eradication of established
B16 melanoma tumors, and prolonged tumor-free survival
[127]. Thus, if the numbers of adoptively transferredwww.sciencedirect.com
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clinic, and safety mechanisms like dual/combinatorial
antigen recognition and split signaling [128,129], inhibi-
tory CAR [130], or suicide gene incorporation [131–133],
are implemented to minimize ‘on target, off site’ toxicity,
an important consideration for this potent therapy [134],
the transfer of T cell populations targeting both the tumor
and its vasculature could prove highly beneficial for the
treatment of advanced cancer patients.
Combinatorial treatment approaches
Administration of antiangiogenic drugs as single agents has
produced only modest clinical responses with no long-term
survival benefits [135–137]. Similarly, vasculature disrupt-
ing agents, drugs designed to destroy existing vessels by
destabilizing microtubules etc. and create central tumor
necrosis, have shown limited efficacy along with extensive
toxicity, even in combination with chemotherapy (drugs
that interfere with cell division by inhibiting genes in-
volved in DNA replication or metabolism), in clinical trials
[138]. When given in combination with chemotherapy,
whereas, the antiangiogenic mAb bevacizumab (Avastin)
led to a remarkable 5 month increase in survival time for
colorectal cancer patients [139] likely because the anti-
VEGF treatment normalized the tumor vasculature thus
enabling enhanced oxygen and drug delivery [34]. For such
outcomes, both timing and dosage of the antiangiogenic
therapy is vital so that the accompanying drugs are admin-
istered when the vessels have normalized (normalization is
a transient state of enhanced vessel perfusion) and so that
the vasculature is not damaged to an extent that it is
inhibitory to drug delivery, or leads to hypoxia and/or
harms normal tissues.
Another successful combination that has been tested is
vasculature targeting plus chemotherapy and active immu-
notherapy [140]. It is worth noting that conventional cyto-
toxic chemotherapeutics such as cyclophosphamide, when
given at lower doses and more frequently, this is referred to
as metronomic chemotherapy, can affect the endothelium
and have anti-angiogenic properties themselves, through
the upregulation, for example, of thrombospondin 1 (TSP1
is a component of the extracellular matrix and an endoge-
nous inhibitor of angiogenesis [141]). Moreover, the effi-
cacy of metronomic chemotherapy increases when
administered in combination with antiangiogenic drugs
[142–144]. In a recent trial we observed anti-tumor
responses and clinical benefit for some patients with recur-
rent stage III/IV ovarian cancer vaccinated with autologous
DCs pulsed with tumor cell lysate in combination with
bevacizumab and oral metronomic cyclophosphamide
[9,145]. Several trials are currently underway to investigate
the potential benefits of combining the anti-angiogenic
drugs bevacizumab and sunitinib with immune check-
point blockade antibodies (anti-PD-1 and anti-CTLA-4)
and with DC vaccines [146]. It should be mentioned,
however, that some combination therapies have failed.www.sciencedirect.com For example, in a multi-institutional clinical trial, meta-
static colorectal cancer patients were randomly treated
with capecitabine, oxaliplatin, and bevacizumab with or
without cetuximab (a mAb against EGFR), and unfortu-
nately, the four-drug combination led to significantly
shorter progression-free survival time and inferior quality
of life [147]. A similar outcome occurred for metastatic
colorectal cancer patients treated with panitumumab (an-
other anti-EGFR mAb) along with folinic acid, fluorouracil,
oxaliplatin and bevacizumab. Thus, careful pre-clinical
assessment of drug combinations is critical.
Conclusions
There is strong evidence that tumor infiltration by T
lymphocytes is associated with good patient prognosis for
many types of cancer including colorectal, ovarian, breast
and melanoma. The tumor vasculature, however, consti-
tutes an important barrier to T cells by actively blocking
extravasation into the tumor through the deregulation of
adhesion molecules including ICAM-1 and VCAM-1
[85], by suppressing them with inhibitory receptors like
PD-L1 and molecules such as IL-6 and IL-10, and even
by targeting them for death by FasL expression [22,57].
Several therapeutic approaches have been developed to
break the tumor endothelial barrier and have further been
shown to act synergistically with active and adoptive
immunotherapies. Given the heterogeneity of solid
tumors (different immune cell infiltrates, stromal compo-
sition, level of vascularization, etc.), well-designed pre-
clinical and clinical studies are warranted to identify
optimal combinations of antiangiogenic drugs and immu-
notherapeutic treatments for each type. This will require
extensive monitoring of changes in tumor vascularity and
the patient’s immunity pre- and post-treatment, determi-
nation of immune biomarkers to measure antiangiogenic
responses, and continuous efforts to identify additional
tumor EC targets. The optimal doses as well as the
scheduling of the treatment modalities should be taken
under consideration to avoid toxic side-effects and maxi-
mize clinical effectiveness. Overall there is strong evi-
dence that targeting the tumor vasculature to enhance T
cell activity improves patient outcome and tumor vascu-
lature normalization may one day be a standard of care for
the treatment of solid tumors.
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